Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:40:55.958Z.
Consensus retrieved: 2026-10-06T09:06:53.732Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:40:55.958Z.
Quote observation: 2026-10-06T14:39:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Forward PE Ratio (N/A) = Dated Quote Price ($2.48) / Consensus Forward EPS ($-3.75)
FORWARD PE RATIO
N/A
Atossa Therapeutics, Inc.
Market Cap
$24.74M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.74M | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.34M | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.33M | N/A |
| InspireMD, Inc. (NSPR)vs › | $27.68M | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.64M | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.84M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.43M | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.22M | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.59M | N/A |
| CervoMed Inc. (CRVO)vs › | $29.63M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.75 | $-4.09 – $-3.24 | 2 | n/m |
| 2027-12-31 | $-2.78 | $-3.88 – $-2.06 | 2 | n/m |
| 2028-12-31 | $2.71 | $-2.38 – $7.81 | 2 | 0.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
